ATE293976T1 - Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen - Google Patents

Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen

Info

Publication number: ATE293976T1
Authority: AT; Austria
Prior art keywords: tofisopam; compounds; seizures; treatment; conseus
Prior art date: 2001-05-18

Application number

AT02253420T

Other languages

English (en)

Inventor

Steven M Leventer

Robert Kucharik

Original Assignee

Vela Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-05-18

Filing date

2002-05-16

Publication date

2005-05-15

2002-05-16 Application filed by Vela Pharmaceuticals Inc filed Critical Vela Pharmaceuticals Inc

2005-05-15 Application granted granted Critical

2005-05-15 Publication of ATE293976T1 publication Critical patent/ATE293976T1/de

Links

229960002501 tofisopam Drugs 0.000 title abstract 3
238000011282 treatment Methods 0.000 title abstract 2
150000001875 compounds Chemical class 0.000 title 2
229940079593 drug Drugs 0.000 title 1
239000003814 drug Substances 0.000 title 1
238000011321 prophylaxis Methods 0.000 title 1
206010010904 Convulsion Diseases 0.000 abstract 4
239000000203 mixture Substances 0.000 abstract 3
RUJBDQSFYCKFAA-HNNXBMFYSA-N (5r)-1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5h-2,3-benzodiazepine Chemical compound C1([C@H](C(=NN=2)C)CC)=CC(OC)=C(OC)C=C1C=2C1=CC=C(OC)C(OC)=C1 RUJBDQSFYCKFAA-HNNXBMFYSA-N 0.000 abstract 2
230000036461 convulsion Effects 0.000 abstract 2
230000001773 anti-convulsant effect Effects 0.000 abstract 1
239000001961 anticonvulsive agent Substances 0.000 abstract 1
229960003965 antiepileptics Drugs 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Psychiatry (AREA)
Addiction (AREA)
Psychology (AREA)
Virology (AREA)
Tropical Medicine & Parasitology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
AIDS & HIV (AREA)
Molecular Biology (AREA)
Hospice & Palliative Care (AREA)
Communicable Diseases (AREA)
Dermatology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Respiratory Apparatuses And Protective Means (AREA)
Medicinal Preparation (AREA)

AT02253420T 2001-05-18 2002-05-16 Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen ATE293976T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US29202601P	2001-05-18	2001-05-18
US10/008,516 US6649607B2 (en)	2001-05-18	2001-11-08	Compositions and methods for treating or preventing convulsions or seizures

Publications (1)

Publication Number	Publication Date
ATE293976T1 true ATE293976T1 (de)	2005-05-15

Family

ID=26678275

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02253420T ATE293976T1 (de)	2001-05-18	2002-05-16	Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen

Country Status (13)

Country	Link
US (3)	US6649607B2 (de)
EP (1)	EP1262184B1 (de)
JP (2)	JP2003012518A (de)
AT (1)	ATE293976T1 (de)
AU (2)	AU3702802A (de)
BR (1)	BR0201862A (de)
CA (1)	CA2381637A1 (de)
DE (1)	DE60203847T2 (de)
ES (1)	ES2241962T3 (de)
GB (1)	GB2377636A (de)
IL (1)	IL149134A (de)
NZ (1)	NZ518675A (de)
WO (1)	WO2002094189A2 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6649607B2 (en) *	2001-05-18	2003-11-18	Vela Pharmaceuticals, Inc.	Compositions and methods for treating or preventing convulsions or seizures
AU2003263357B2 (en) *	2002-09-13	2009-02-26	Motac Neuroscience Limited	Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
DK1539135T3 (da) *	2002-09-17	2007-09-17	Motac Neuroscience Ltd	Behandling af dyskinesi
US6864251B2 (en) *	2002-12-03	2005-03-08	Vela Pharmaceuticals, Inc.	Treatment of LTB4-mediated inflammatory disorders with optically-pure (R)-2,3-benzodiazepines
WO2004050040A2 (en) *	2002-12-03	2004-06-17	Vela Pharmaceuticals, Inc.	Pharmaceutical composition of 1-(3,4-dimethoxyphenyl)-4-methyl-5-ethyl-7-methoxy-8-hydroxy-5h-2,3-benzodiazepine and uses thereof
WO2004069155A2 (en) *	2002-12-03	2004-08-19	Vela Pharmaceuticals, Inc.	Pharmaceutical composition of 1-(3-hydroxy-4-methoxyphenyl)-4-methyl-5-ethyl-7,8-dimethoxy-5h-2,3-benzodiazepine and uses therof
US6638928B1 (en) *	2002-12-03	2003-10-28	Vela Pharmaceuticals, Inc.	Treatment of irritable bowel syndrome and nonulcer dyspepsia with substituted 2,3-benzodiazepines
US7265106B2 (en)	2003-05-09	2007-09-04	Vela Aquisition Corporation	Method for isolating (R)-tofisopam
US20070021412A1 (en) *	2003-05-16	2007-01-25	Vela Pharmaceuticals, Inc.	Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S) 2,3-benzodiazepine
CA2525273C (en) *	2003-05-16	2012-04-17	Vela Pharmaceuticals, Inc.	Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (r) 2,3-benzodiazepine
US20050288277A1 (en) *	2004-06-25	2005-12-29	Kucharik Robert F	Treatment of gastrointestinal dysfunction and related stress with an enantiomerically-pure (S)-2,3-benzodiazepine
US20070032479A1 (en) *	2003-12-03	2007-02-08	Leventer Steven M	Treatment of inflammatory disorders of the epithelium with low dose 2,3-benzodiazepines
US20060111743A1 (en) *	2004-11-19	2006-05-25	Gurney Harry C Jr	Method for arresting seizure activity
US7541355B2 (en) *	2005-05-23	2009-06-02	Vela Acquisition Corporation	Conversion process for 2,3-benzodiazepine enantiomers
WO2007082546A1 (en) *	2006-01-20	2007-07-26	H. Lundbeck A/S	Use of tofisopam as a pde10a inhibitor
JP2008174495A (ja) *	2007-01-19	2008-07-31	Reverse Proteomics Research Institute Co Ltd	創薬標的タンパク質及び標的遺伝子、並びにスクリーニング方法
US9408852B2 (en)	2011-07-27	2016-08-09	Pharmos Corporation	Method of lowering serum uric acid levels with (S)-tofisopam
CN102836162A (zh) *	2012-04-10	2012-12-26	珠海亿邦制药股份有限公司	一种以托非索泮为活性成分的口服固体制剂及其应用
CN105363006A (zh) *	2015-12-16	2016-03-02	张景英	一种用于护理治疗小儿高热惊厥的中药药膏

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK118660B (da)	1966-12-09	1970-09-21	Egyt Gyogyszervegyeszeti Gyar	Analogifremgangsmåde til fremstilling af 1-(3',4'-dimethoxyphenyl)-3-methyl-4-ethyl-6,7-dimethoxy-isoquinolin-N-imid.
ZA712798B (en)	1970-11-06	1972-02-23	Egyt Gyogyszervegyeszeti Gyar	New,pharmaceutically active 2,3-diazabicyclo(5.4.0)undecapentaene derivative and process for preparing same
HU179018B (en)	1978-10-19	1982-08-28	Gyogyszerkutato Intezet	Process for producing new 5h-2,3-benzodiazepine derivatives
HU186760B (en)	1981-03-12	1985-09-30	Gyogyszerkutato Intezet	Process for preparing 3,4-dihydro-5h-2,3-aenzodiazepine derivatives
HU191698B (en)	1984-07-27	1987-03-30	Gyogyszerkutato Intezet	Process for producing new 1-aryl-5h-2beta-benzodiazepines
HU198494B (en)	1986-08-15	1989-10-30	Gyogyszerkutato Intezet	Process for producing new 3,4-dihydro-5h-2,3-benzodiazepine derivative and acid addition salts thereof, as well as pharmaceutical compositions comprising same
GB9009861D0 (en)	1990-05-02	1990-06-27	Glaxo Group Ltd	Chemical compounds
HU207055B (en)	1990-10-17	1993-03-01	Gyogyszerkutato Intezet	Process for producing new 5h-2,3-benzodiazepine derivative and pharmaceutical compositions comprising same
HU206719B (en)	1990-12-21	1992-12-28	Gyogyszerkutato Intezet	Process for producing 1-/4-acylamino-phenyl/-7,8-methylenedioxy-5h-2,3-benzodiazepine derivatives, acid addicional salts and pharmaceutical compositions containing them
US5521174A (en)	1990-12-21	1996-05-28	Gyogyszerkutato Intezet Kv.	N-acyl-2,3-benzodiazepine derivatives and a method of treating spasms of the skeletal musculature therewith
US5519019A (en)	1990-12-21	1996-05-21	Gyogyszerkutato Intezet	N-acyl-2,3-benzoidazepine derivatives, pharmaceutical compositions containing them and process for preparing same
US5639751A (en)	1990-12-21	1997-06-17	Cyogyszerkutato Intezet Kft	N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
HU219778B (hu)	1990-12-21	2001-07-30	Gyógyszerkutató Intézet Közös Vállalat	Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények
US6017965A (en)	1993-02-08	2000-01-25	Nps Pharmaceuticals, Inc.	Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
US6071970A (en)	1993-02-08	2000-06-06	Nps Pharmaceuticals, Inc.	Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
HU219777B (hu)	1993-07-02	2001-07-30	Gyógyszerkutató Intézet Kft.	Optikailag aktív 1-(4-nitro-fenil)-4-metil-7,8-metiléndioxi-3,4-dihidro-5H-2,3-benzodiazepin és eljárás előállítására
DK1157992T3 (da)	1994-08-31	2005-10-24	Lilly Co Eli	Dihydro-2,3-benzodiazepinederivativer
HU224435B1 (hu)	1995-02-09	2005-10-28	EGIS Gyógyszergyár Rt.	Benzodiazepin-származékok, eljárás előállításukra, alkalmazásukra és ezeket tartalmazó gyógyászati készítmények
US5891871A (en)	1996-03-21	1999-04-06	Cocensys, Inc.	Substituted 2,3-benzodiazepin-4-ones and the use thereof
PT1124556E (pt)	1998-10-27	2004-10-29	Vela Pharmaceuticals Inc	Utilizacao de (r)-tofisopam opticamente puro para tratamento e prevencao de perturbacoes da ansiedade e sua composicao
US6080736A (en)	1999-10-27	2000-06-27	Janus Pharmaceuticals, Inc.	Methods and compositions for treating and preventing anxiety and anxiety disorders using optically pure (R) tofisopam
US6649607B2 (en) *	2001-05-18	2003-11-18	Vela Pharmaceuticals, Inc.	Compositions and methods for treating or preventing convulsions or seizures

2001
- 2001-11-08 US US10/008,516 patent/US6649607B2/en not_active Expired - Lifetime
2002
- 2002-04-11 CA CA002381637A patent/CA2381637A1/en not_active Abandoned
- 2002-04-15 IL IL149134A patent/IL149134A/en not_active IP Right Cessation
- 2002-04-26 AU AU37028/02A patent/AU3702802A/en not_active Abandoned
- 2002-05-01 NZ NZ518675A patent/NZ518675A/en unknown
- 2002-05-15 JP JP2002139802A patent/JP2003012518A/ja active Pending
- 2002-05-16 ES ES02253420T patent/ES2241962T3/es not_active Expired - Lifetime
- 2002-05-16 AT AT02253420T patent/ATE293976T1/de not_active IP Right Cessation
- 2002-05-16 EP EP02253420A patent/EP1262184B1/de not_active Expired - Lifetime
- 2002-05-16 GB GB0211247A patent/GB2377636A/en not_active Withdrawn
- 2002-05-16 DE DE60203847T patent/DE60203847T2/de not_active Expired - Fee Related
- 2002-05-17 AU AU2002303817A patent/AU2002303817A1/en not_active Abandoned
- 2002-05-17 WO PCT/US2002/015996 patent/WO2002094189A2/en not_active Ceased
- 2002-05-17 BR BR0201862-4A patent/BR0201862A/pt not_active IP Right Cessation
2003
- 2003-07-23 US US10/625,754 patent/US7078398B2/en not_active Expired - Fee Related
2006
- 2006-03-24 US US11/388,399 patent/US20060166976A1/en not_active Abandoned
2007
- 2007-07-17 JP JP2007185953A patent/JP2007262096A/ja active Pending

Also Published As

Publication number	Publication date
US20030055048A1 (en)	2003-03-20
CA2381637A1 (en)	2002-11-18
US6649607B2 (en)	2003-11-18
WO2002094189A3 (en)	2003-04-10
BR0201862A (pt)	2003-03-25
AU2002303817A1 (en)	2002-12-03
JP2007262096A (ja)	2007-10-11
AU3702802A (en)	2002-11-21
GB0211247D0 (en)	2002-06-26
EP1262184A1 (de)	2002-12-04
DE60203847T2 (de)	2006-01-26
US7078398B2 (en)	2006-07-18
NZ518675A (en)	2003-07-25
WO2002094189A2 (en)	2002-11-28
ES2241962T3 (es)	2005-11-01
IL149134A (en)	2007-06-17
GB2377636A (en)	2003-01-22
IL149134A0 (en)	2002-11-10
EP1262184B1 (de)	2005-04-27
DE60203847D1 (de)	2005-06-02
JP2003012518A (ja)	2003-01-15
US20050075329A1 (en)	2005-04-07
US20060166976A1 (en)	2006-07-27

Legal Events

Date	Code	Title	Description
2005-10-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE293976T1 (de)	2005-05-15	Verbindungen enthaltend s-tofisopam sowie verwendung dieser verbindungen zur herstellung eines medikamentes zur behandlung oder prophylaxe von krämpfen und anfällen
ATE523194T1 (de)	2011-09-15	Bis(thiohydrazidamide) in kombination mit taxol für die behandlung von krebs
ATE396174T1 (de)	2008-06-15	Hydroxyalkylaminderivate als beta-secretase- inhibitoren und deren verwendung zur behandlung der alzheimerschen krankheit oder ähnlicher krankheiten
ATE355374T1 (de)	2006-03-15	Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
ATE253932T1 (de)	2003-11-15	Verwendung von erythropoietin oder erythropoietin-derivaten zur behandlung von cerebralen ischämien
ATE489379T1 (de)	2010-12-15	2-oxo-1,3,5-perhydrotriazapinderivate, die sich zur behandlung von hyperproliferativen, angiogenen und entzündlichen erkrankungen eignen
TW200420550A (en)	2004-10-16	Thiazole compounds for the treatment of neurodegenerative disorders
ATE414524T1 (de)	2008-12-15	Verwendung von myoblasten zur herstellung eines medikaments zur behandlung der stressbedingten harninkontinenz
ATE439833T1 (de)	2009-09-15	Pharmazeutische zubereitung enthaltend ein catechin, ascorbinsäure, prolin und lysin zur behandlung von neoplastischen krankheiten
DE602004021847D1 (de)	2009-08-13	Verfahren zur prävention und behandlung von diabetes mit neurturin
ATE309817T1 (de)	2005-12-15	Pharmazeutische zusammensetzung die trkaig2 enthält zur verwendung in der vorbeugung und/oder behandlung von krebs
ATE363923T1 (de)	2007-06-15	Verwendung von flumazenil zur herstellung eines medikaments für die behandlung von kokainabhängigkeit
ATE252383T1 (de)	2003-11-15	Verwendung von 2-methyl-thiazolidin-2,4- dicarbonsäure und / oder ihrer physiologisch verträglichen salze zur herstellung eines medikaments zur behandlung von krebserkrankungen
DE60229240D1 (de)	2008-11-20	Verwendung eines analoges des vitamins d3 zur behandlung des autoimmunen diabetes
ATE388719T1 (de)	2008-03-15	Verwendung von feigenkaktus (opuntia) zur herstellung eines medikaments zur behandlung von depressionen
DE602004030661D1 (de)	2011-02-03	Verwendung von kahalalide verbindungen zur herstellung eines arzneimittels zur behandlung von psoriasis
ATE408602T1 (de)	2008-10-15	Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
ATE315387T1 (de)	2006-02-15	Verwendung von substituierten 6- dimethylaminomethyl-1-phenyl- cyclohexanverbindungen zur therapie der harninkontinenz
DE60219680D1 (de)	2007-05-31	Amin-1,2- und -1,3-diolverbindungen und deren verwendung zur behandlung von alzheimer-krankheit
DE60227008D1 (de)	2008-07-17	Neue thiophenacylhydrazinoderivate, verfahren zu deren herstellung, deren verwendung als arzneimittel, pharmazeutische zusammensetzungen und neue anwendungen
DE69421705D1 (de)	1999-12-23	Verwendung von Efaroxan und dessen Derivaten zur Herstellung eines Arzneimittels zur Behandlung neurogenerativer Erkrankungen
ATE473737T1 (de)	2010-07-15	Verwendung von 2,3-dehydronaringenin-derivaten zur behandlung von entzündungsprozessen und diese derivate enthaltende pharmazeutische zusammensetzung
DE60313344D1 (de)	2007-05-31	Verwendung von 4-pyridylmethyl-phthalazin-derivaten zur herstellung eines medikaments zur behandlung von myelodysplastischen syndromen
DE69915849D1 (de)	2004-04-29	Verwendung von gnrh analogen zur behandlung von schizophrenie
DE50302825D1 (de)	2006-05-18	2-methylthiazolidin-2,4-dicarbonsaeure und deren salze zur behandlung von neurodegenerativen erkrankungen